everolimus pharmagen 5 mg tablety
pharmagen cz s.r.o., Česká republika - everolimus - 44 - cytostatica
everolimus pharmagen 2,5 mg tablety
pharmagen cz s.r.o., Česká republika - everolimus - 44 - cytostatica
ymm-1
cis biointernational bp 32, francúzsko - ytrium (90y) citrátový koloid - 88 - radiopharmaca
everolimus accord 10 mg tablety
accord healthcare polska sp. z o.o., poľsko - everolimus - 44 - cytostatica
everolimus accord 5 mg tablety
accord healthcare polska sp. z o.o., poľsko - everolimus - 44 - cytostatica
everolimus accord 2,5 mg tablety
accord healthcare polska sp. z o.o., poľsko - everolimus - 44 - cytostatica
thiotepa riemser
esteve pharmaceuticals gmbh - thiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastické činidlá - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.
cegfila (previously pegfilgrastim mundipharma)
mundipharma corporation (ireland) limited - pegfilgrastím - neutropénia - immunostimulants, - zníženie trvania neutropénie a výskytu febrilnej neutropénie u dospelých pacientov liečených cytotoxickou chemoterapiou kvôli malígnemu (s výnimkou chronickej myeloidnej leukémie a myelodysplastických syndrómov).
celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - hydrochlorid doxorubicínu - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastické činidlá - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).
18-fd-glukóza inj.
Újv Řež, a.s., Česká republika - fludeoxyglukóza (18f) - 88 - radiopharmaca